ライフサイエンスコーパス: gastroesophageal

1 Gastroesophageal acid reflux at each of the pH sensors e

2 specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA).

3 long OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/

4 Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious an

5 Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a post

6 atients with advanced, untreated gastric, or gastroesophageal adenocarcinoma.

7 e patient outcomes in patients with advanced gastroesophageal adenocarcinoma.

8 , nonperiodontal abscess from a patient with gastroesophageal adenocarcinoma.

9 nset in 6 of 16 patients (38%): prostate and gastroesophageal adenocarcinomas, myeloma, melanoma, col

10 ce of the ischemia after gastrointestinal or gastroesophageal anastomosis.

11 Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a molecular

12 Many miRNAs are dysregulated in gastroesophageal cancer cells via alterations in transcr

13 ative chemotherapy plus surgery for operable gastroesophageal cancer from July 1, 1994, through April

14 Advanced gastroesophageal cancer is an incurable condition and mo

15 phase III trials for patients with advanced gastroesophageal cancer is increasing and that is welcom

16 SI, and survival in patients with resectable gastroesophageal cancer randomized to surgery alone or p

17 Gastroesophageal cancer resections are associated with s

18 to reintervene and rescue patients following gastroesophageal cancer resections in England.

19 rs of nutritional status among patients with gastroesophageal cancer to determine whether any such as

20 er, 5108/24,458; rectal cancer, 3248/15,552; gastroesophageal cancer, 3854/18,477; prostate cancer, 1

21 The incidence of gastroesophageal cancers is increasing each year, but de

22 miRNAs contribute to gastroesophageal carcinogenesis by altering expression o

23 ater understanding of the roles of miRNAs in gastroesophageal carcinogenesis could provide insights i

24 oncoding RNAs that have been associated with gastroesophageal carcinogenesis.

25 It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and h

26 Gastroesophageal function was assessed by clinical valid

27 Gastroesophageal function was evaluated using a clinical

28 sease-specific survival (DSS) for resectable gastroesophageal (GE) junction and gastric adenocarcinom

29 chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is as

30 iate esophageal versus gastric epithelium in gastroesophageal junction (GEJ) biopsies, the histology

31 Lewis esophagectomy (TTIL) for esophageal or gastroesophageal junction (GEJ) cancer.

32 October 2006 to October 2008: 22 gastric, 20 gastroesophageal junction (GEJ), and two esophagus.

33 tic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ).

34 ction of stage IB through IV (M0) gastric or gastroesophageal junction adenocarcinoma were randomly a

35 gnosis in patients with distal esophageal or gastroesophageal junction adenocarcinoma who have receiv

36 rpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Tri

37 ion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative

38 nts with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

39 radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated s

40 veness in reducing mortality from esophageal/gastroesophageal junction adenocarcinomas has not been e

41 ed by gastroesophageal reflux disease in the gastroesophageal junction and associated with tumorigene

42 n of DeltaNp73 in a large number of gastric, gastroesophageal junction and esophageal tumors.

43 ined as eradication of IM (in esophageal and gastroesophageal junction biopsy specimens), documented

44 reviously untreated metastatic esophageal or gastroesophageal junction cancer were randomly assigned

45 otherapy for locally advanced esophageal and gastroesophageal junction cancers is based on a few posi

46 T1 adenocarcinoma of the distal esophagus or gastroesophageal junction from January 1985 to December

47 Implantation of a MSA around the gastroesophageal junction has been shown to be a safe an

48 patients with carcinoma of the esophagus or gastroesophageal junction has been surgery, although pri

49 ith adenocarcinoma of the gastric cardia and gastroesophageal junction have no history of reflux.

50 We studied the gastroesophageal junction in asymptomatic volunteers wit

51 the lower frequency of tumors arising at the gastroesophageal junction in comparison with distal gast

52 carcinomas arising in the stomach or in the gastroesophageal junction in patients with HER2-positive

53 thoracic esophageal carcinoma, including the gastroesophageal junction tumors (Siewert I), were rando

54 ch, carina, and one vertebral body above the gastroesophageal junction was 13.9, 14.3, and 15.1 mm, r

55 ble adenocarcinoma of the lower esophagus or gastroesophageal junction were reviewed.

56 Manometric values of "gastroesophageal junction" significantly increased at 12

57 py of local and locally advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas,

58 o III cancer of the mid-/distal-esophagus or gastroesophageal junction, measurable disease, and Easte

59 asia seen in some cases, particularly at the gastroesophageal junction.

60 system delivers radiofrequency energy to the gastroesophageal junction.

61 ination after radiofrequency ablation at the gastroesophageal junction.

62 metastatic adenocarcinoma of the stomach and gastroesophageal junction.

63 correlated with the (18)F-FDG uptake at the gastroesophageal junction.

64 ogy, and recurrence patterns associated with gastroesophageal malignancies suggest the need to split

65 development of cachexia among patients with gastroesophageal malignancy.

66 with advanced lung, colorectal, pancreatic, gastroesophageal, or breast cancer between 1998 and 2005

67 doscopic capture from patients with gastric, gastroesophageal, or esophageal cancer who are administe

68 moderate to severe abdominal pain, a severe gastroesophageal reflex, and moderate to severe depressi

69 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 point), and depression (+1 p

70 omorbidities were allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinusitis (37.9%), nasa

71 The contribution of gastroesophageal reflux (GER) and vagal function to esop

72 Dental erosion is a complication of gastroesophageal reflux (GER) in adults; in children, it

73 Gastroesophageal reflux (GER) is a disorder that is comm

74 The prevalence of abnormal acid gastroesophageal reflux (GER) is higher in patients with

75 Asymptomatic gastroesophageal reflux (GER) is prevalent in children w

76 f a disease engendered more controversy than gastroesophageal reflux (GER), a highly prevalent condit

77 symptom relief, prevalence of post-treatment gastroesophageal reflux (GER), and complications.

78 sts with erosive tooth wear have significant gastroesophageal reflux (GERD), despite minor reflux sym

79 n the temporal association between cough and gastroesophageal reflux (GOR) in patients in whom non-GO

80 ocephaly, developed intellectual disability, gastroesophageal reflux and a seizure disorder.

81 There were 7 million diagnoses of gastroesophageal reflux and almost 4 million diagnoses o

82 tissue remodeling is associated with chronic gastroesophageal reflux and constitutes a premalignant l

83 BE is associated with chronic gastroesophageal reflux and esophageal cancer.

84 because of both mechanical effects promoting gastroesophageal reflux and nonmechanical effects.

85 also significant improvements in symptoms of gastroesophageal reflux and rhinitis, bronchial reversib

86 index greater than 4 on pH monitoring and/or gastroesophageal reflux and/or herniated wrap on upper g

87 Gastroesophageal reflux causes inflammation and intestin

88 ng bowel habit (15%), constipation (13%) and gastroesophageal reflux disease (12%).

89 lipidemia (24.5%), hypertension (21.9%), and gastroesophageal reflux disease (17.3%).

90 The presence of gastroesophageal reflux disease (26%), esophageal strict

91 ere rhinitis (84.0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%).

92 gus (n = 1059) with those from subjects with gastroesophageal reflux disease (gastroesophageal reflux

93 .1; 95% confidence interval [CI], 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI,

94 lin, leptin, and ghrelin are associated with gastroesophageal reflux disease (GERD) and Barrett's eso

95 We examined the incidence and predictors of gastroesophageal reflux disease (GERD) and dyspepsia and

96 Skinner to the understanding of gastroesophageal reflux disease (GERD) and its complicat

97 might represent an alternative treatment of gastroesophageal reflux disease (GERD) and may provide d

98 has enormous potential for the treatment of gastroesophageal reflux disease (GERD) and other esophag

99 The advent of the Montreal definition of gastroesophageal reflux disease (GERD) and the Rome III

100 agement of extraesophageal manifestations of gastroesophageal reflux disease (GERD) and to compare th

101 Lung transplant recipients with documented gastroesophageal reflux disease (GERD) are at increased

102 Current diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal an

103 Management of gastroesophageal reflux disease (GERD) commonly starts w

104 t clear why only a minority of patients with gastroesophageal reflux disease (GERD) develop Barrett's

105 .4)] were included; 70% had been treated for gastroesophageal reflux disease (GERD) during infancy.

106 The histologic changes associated with acute gastroesophageal reflux disease (GERD) have not been stu

107 The aim was to compare recurrence of gastroesophageal reflux disease (GERD) in children rando

108 RAs) are frequently used in the treatment of gastroesophageal reflux disease (GERD) in children; howe

109 n (TF) can decrease or eliminate features of gastroesophageal reflux disease (GERD) in some patients

110 Gastroesophageal reflux disease (GERD) is a common diagn

111 It has been suggested that gastroesophageal reflux disease (GERD) is a risk factor

112 Gastroesophageal reflux disease (GERD) is associated wit

113 The pathogenesis of gastroesophageal reflux disease (GERD) is complex and in

114 illustrated by the Montreal classification, gastroesophageal reflux disease (GERD) is much more than

115 Gastroesophageal reflux disease (GERD) is prevalent worl

116 ump inhibitor (PPI) therapy in patients with gastroesophageal reflux disease (GERD) is reported in up

117 Gastroesophageal reflux disease (GERD) is the most commo

118 Gastroesophageal reflux disease (GERD) is the most preva

119 Gastroesophageal reflux disease (GERD) is the strongest

120 Many individuals with gastroesophageal reflux disease (GERD) never visit their

121 f an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it pre

122 Most patients with gastroesophageal reflux disease (GERD) report that stres

123 has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite

124 Patients with gastroesophageal reflux disease (GERD) who are not respo

125 tailed critique of objective measurements of gastroesophageal reflux disease (GERD) would improve man

126 BS), 3.0; dyspepsia, 1.8; constipation, 3.9; gastroesophageal reflux disease (GERD), 9.7.

127 cluding Crohn disease (CrD), celiac disease, gastroesophageal reflux disease (GERD), and eosinophilic

128 frequency of irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and overactive b

129 rm use of PPIs for three common indications: gastroesophageal reflux disease (GERD), Barrett's esopha

130 n several pathophysiological states, such as gastroesophageal reflux disease (GERD), functional dyspe

131 Gastroesophageal reflux disease (GERD), functional dyspe

132 Barrett esophagus, a complication of gastroesophageal reflux disease (GERD), predisposes pati

133 Unlike gastroesophageal reflux disease (GERD), whose symptoms c

134 responders and treatment-naive patients with gastroesophageal reflux disease (GERD).

135 n accurate method for diagnosing adults with gastroesophageal reflux disease (GERD).

136 s for a range of medical disorders including gastroesophageal reflux disease (GERD).

137 only used in the diagnosis and management of gastroesophageal reflux disease (GERD).

138 ctional gastrointestinal disorders (FGD) and gastroesophageal reflux disease (GERD).

139 e existing endoscopy-based interventions for gastroesophageal reflux disease (GERD).

140 a significant increase in the prevalence of gastroesophageal reflux disease (GERD).

141 one combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD).

142 en fundoplication (CNF) for the treatment of gastroesophageal reflux disease (GERD).

143 dal anti-inflammatory drugs) and symptoms of gastroesophageal reflux disease (GERD).

144 urgical option for patients with early-stage gastroesophageal reflux disease (GERD).

145 procedure of choice for obese patients with gastroesophageal reflux disease (GERD).

146 y risk factors for both BE and EA is chronic gastroesophageal reflux disease (GERD).

147 cations in adults were dysphagia (70.1%) and gastroesophageal reflux disease (GERD)/heartburn (27.1%)

148 We also included 10 patients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 w

149 n 2002 and 2005 were matched to persons with gastroesophageal reflux disease (GERD; n = 316) and to p

150 nths after fundoplication for PPI-refractory gastroesophageal reflux disease (n = 14 270 degrees LPF

151 (n = 296 cases) were matched to persons with gastroesophageal reflux disease (n = 308) without Barret

152 ad EoE (n = 17), indeterminate EoE (n = 15), gastroesophageal reflux disease (n = 7), or normal esoph

153 ether patient-identified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting,

154 er improvement in quality of life related to gastroesophageal reflux disease and a 50% or greater red

155 patterns from biopsies of patients with EoE, gastroesophageal reflux disease and controls.

156 allenges to diagnosis, including the role of gastroesophageal reflux disease and proton pump inhibito

157 75-year-old woman with a medical history of gastroesophageal reflux disease and type II diabetes pre

158 e mechanisms involved in the pathogenesis of gastroesophageal reflux disease are complex and multifac

159 The high reoperation rate and incidence of gastroesophageal reflux disease are concerning.

160 pump inhibitors and has focused attention on gastroesophageal reflux disease as a causative factor in

161 We prospectively assessed 100 patients with gastroesophageal reflux disease before and after sphinct

162 iteria consisted of a confirmed diagnosis of gastroesophageal reflux disease by an abnormal esophagea

163 , screening 50-year-old men with symptoms of gastroesophageal reflux disease by Cytosponge is cost ef

164 emerging disease that is distinguished from gastroesophageal reflux disease by the expression of a u

165 suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures.

166 Gastroesophageal reflux disease complicated by Barrett's

167 95% confidence interval [CI]: 1.04-2.67) or gastroesophageal reflux disease controls (OR = 1.61; 95%

168 bjects with gastroesophageal reflux disease (gastroesophageal reflux disease controls, n = 1332), and

169 Early aggressive surgical treatment of gastroesophageal reflux disease decreases the rate of br

170 es for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive

171 ugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, a

172 Most patients with gastroesophageal reflux disease experience symptomatic r

173 rm outcome of ARS in pediatric patients with gastroesophageal reflux disease have shown good to excel

174 months improved in patients with normal GE (Gastroesophageal Reflux Disease Health-Related Quality o

175 imary laparoscopic antireflux surgery due to gastroesophageal reflux disease in adults (>18 years).

176 related to the acidic environment caused by gastroesophageal reflux disease in the gastroesophageal

177 Gastroesophageal reflux disease is a highly prevalent ch

178 Gastroesophageal reflux disease is a highly prevalent di

179 esophageal sphincter (LES) in patients with gastroesophageal reflux disease often has a low resting

180 is (EoE) was historically distinguished from gastroesophageal reflux disease on the basis of histolog

181 ated with EoE (or indeterminate EoE) but not gastroesophageal reflux disease or normal esophagus and

182 ted with a relatively high rate of recurrent gastroesophageal reflux disease requiring treatment, dim

183 Symptoms improved in group A, with the Gastroesophageal Reflux Disease Symptom Assessment Scale

184 men in the United Kingdom with histories of gastroesophageal reflux disease symptoms, assuming the p

185 The history of gastroesophageal reflux disease was highly prevalent in

186 Gastroesophageal reflux disease was identified as an imp

187 De novo gastroesophageal reflux disease was reported in 43.8%.

188 Patients with gastroesophageal reflux disease who have a partial respo

189 structive sleep apnea may be associated with gastroesophageal reflux disease, a strong risk factor fo

190 allergic rhinitis, chronic rhinitis, asthma, gastroesophageal reflux disease, adenotonsillitis, sleep

191 Risk factors evaluated included gastroesophageal reflux disease, alcohol consumption, sm

192 lization for asthma, mechanical ventilation, gastroesophageal reflux disease, and aspiration or other

193 lation), and prior diagnoses (eg, pneumonia, gastroesophageal reflux disease, and other comorbidities

194 the individual to irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer diseas

195 factors for EAC have been identified-mainly gastroesophageal reflux disease, Barrett's esophagus, ob

196 shown to be a safe and effective therapy for gastroesophageal reflux disease, but its effect on the L

197 Symptoms frequently mimic those of gastroesophageal reflux disease, but the diseases are di

198 Risk factors include gastroesophageal reflux disease, central obesity, and sm

199 terms: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

200 lowing: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

201 l gastrointestinal complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Ba

202 This issue provides a clinical overview of gastroesophageal reflux disease, focusing on diagnosis,

203 of the lower esophagus epithelium related to gastroesophageal reflux disease, is the strongest known

204 itant chemical carcinogen treatment leads to gastroesophageal reflux disease, multilayered epithelium

205 With improved understanding of gastroesophageal reflux disease, newer developments in d

206 on airway disease, including rhinosinusitis, gastroesophageal reflux disease, obesity and dysfunction

207 , including history of peptic ulcer disease, gastroesophageal reflux disease, or gastrointestinal ble

208 Too much acid can lead to gastroesophageal reflux disease, peptic ulcer disease, a

209 premorbid prevalence of anxiety, headaches, gastroesophageal reflux disease, sleep apnea, and infect

210 44 patients (52%) had objective findings of gastroesophageal reflux disease, such as esophagitis.

211 Triggered by gastroesophageal reflux disease, the origin of this meta

212 ic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabet

213 Except for gastroesophageal reflux disease, which showed a higher r

214 ministered a modified version of a validated gastroesophageal reflux disease-specific QOL tool to pat

215 Quality of life, measured by the gastroesophageal reflux disease-specific QOL tool, and r

216 Obesity is associated with a risk of gastroesophageal reflux disease.

217 llow-up after ARS in pediatric patients with gastroesophageal reflux disease.

218 180-degree LAF for the surgical treatment of gastroesophageal reflux disease.

219 st frequently performed surgical therapy for gastroesophageal reflux disease.

220 ved cells is a novel potential treatment for gastroesophageal reflux disease.

221 drome (IBS) frequently overlap with those of gastroesophageal reflux disease.

222 gents widely prescribed for the treatment of gastroesophageal reflux disease.

223 to evaluate for the presence of concomitant gastroesophageal reflux disease.

224 thereby conclusively distinguishing it from gastroesophageal reflux disease.

225 fundoplication is an effective treatment for gastroesophageal reflux disease.

226 increasingly recognized disease that mimics gastroesophageal reflux disease.

227 ders, including irritable bowel syndrome and gastroesophageal reflux disease.

228 ery effective and long-lasting treatment for gastroesophageal reflux disease.

229 is a laryngeal symptom that can be caused by gastroesophageal reflux disease; however, treatment outc

230 cough may have abnormal proximal exposure to gastroesophageal reflux documented by HMII that would ha

231 sphincter (UES) to simulated or spontaneous gastroesophageal reflux have shown conflicting results.

232 Subjects reporting nocturnal gastroesophageal reflux in both 1999 and 2010 had more N

233 rtburn with and without regurgitation due to gastroesophageal reflux in the absence of esophageal muc

234 Gastroesophageal reflux is common among patients with po

235 he diagnosis of cough, LPR, or asthma due to gastroesophageal reflux is difficult, as no criterion st

236 Gastroesophageal reflux is the main risk factor for esop

237 allograft injury from donor-directed Abs or gastroesophageal reflux led to new ColV and KAT Abs post

238 As gastroesophageal reflux persists or recurs in 43% of chi

239 There is significant though mild gastroesophageal reflux postoperatively in 46% of patien

240 rative complications, sleep difficulties and gastroesophageal reflux progressively worsened during fo

241 ireflux surgery, 17.7% experienced recurrent gastroesophageal reflux requiring long-term medication u

242 Gastroesophageal reflux scores were higher in overweight

243 based on the modified Rome III criteria) and gastroesophageal reflux symptoms (GERS) in a population-

244 Apoptosis pathway, gastroesophageal reflux symptoms (reflux), higher body m

245 eep apnea and to determine whether nocturnal gastroesophageal reflux symptoms affect the relationship

246 estioned regarding severity of their typical gastroesophageal reflux symptoms and presence of nocturn

247 nal GERD in 1999 (>/=3 episodes of nocturnal gastroesophageal reflux symptoms per week) had an OR of

248 Barrett's esophagus patients with nocturnal gastroesophageal reflux symptoms should be further evalu

249 's esophagus was associated with more severe gastroesophageal reflux symptoms, and nocturnal reflux s

250 al reflux symptoms and presence of nocturnal gastroesophageal reflux symptoms.

251 The rate of gastroesophageal reflux was comparable with prior studie

252 Gastroesophageal reflux was defined by abnormal pH-testi

253 At 6 months, gastroesophageal reflux was evaluated by 24-hour pH test

254 Gastroesophageal reflux was reported in 50.0% (40 vs 27

255 Objective evidence of gastroesophageal reflux was seen in 46% patients postope

256 Gastroesophageal reflux was the most common GI diagnosis

257 Chronic sinusitis and gastroesophageal reflux were also associated with exacer

258 From 1995 to 2003, 461 patients with gastroesophageal reflux were enrolled in 4 randomized co

259 s have failed to demonstrate that preventing gastroesophageal reflux with antireflux surgery halts th

260 Six studies have suggested that gastroesophageal reflux worsens after cholecystectomy.

261 Infantile colic, gastroesophageal reflux, and constipation are the most c

262 pse include neck flexion, airway secretions, gastroesophageal reflux, and sleep deprivation.

263 ralized anxiety disorder, diabetes mellitus, gastroesophageal reflux, bacterial infection, and bone m

264 is used variably to prevent complications of gastroesophageal reflux, but its effectiveness is unprov

265 trophy (SMA) notes that patients suffer from gastroesophageal reflux, constipation and delayed gastri

266 discussed: rhinitis, chronic rhinosinusitis, gastroesophageal reflux, obstructive sleep apnoea, vocal

267 in the postoperative period from SSc-related gastroesophageal reflux, renal impairment, and skin fibr

268 , sex, percent predicted FEV1, self-reported gastroesophageal reflux, St. George's Respiratory Questi

269 pump inhibitors (PPIs) are popular drugs for gastroesophageal reflux, which are now available for lon

270 BACKGROUND & AIMS: Central obesity promotes gastroesophageal reflux, which may be related to increas

271 esophagus and may work synergistically with gastroesophageal reflux.

272 criteria and two with findings secondary to gastroesophageal reflux.

273 leaks and strictures, gastric dilation, and gastroesophageal reflux.

274 Barrett's esophagus segments and persistent gastroesophageal reflux.

275 frequently performed surgical procedure for gastroesophageal reflux.

276 fundoplication for the surgical treatment of gastroesophageal reflux.

277 choanal atresia repair, and/or treatment of gastroesophageal reflux.

278 n, poor overall health, home oxygen use, and gastroesophageal reflux.

279 For gastroesophageal resections combined, adjusted mortality

280 nclude younger age at presentation, previous gastroesophageal surgery or ulcers as an etiology, and a

281 Each type of gastroesophageal tumor has a unique gene expression prof

282 pes of cancer, including HER2-overexpressing gastroesophageal tumors.

283 y is common in cirrhotic patients with acute gastroesophageal variceal bleeding and is an independent

284 a lower rate of abdominal and chest varices, gastroesophageal variceal bleeding and refractory ascite

285 cotropin stimulation test in 157 episodes of gastroesophageal variceal bleeding in 143 patients with

286 Gastroesophageal variceal bleeding in patients with cirr

287 We present a case of a patient with massive gastroesophageal variceal bleeding refractory to numerou

288 utcomes of patients with cirrhosis and acute gastroesophageal variceal bleeding remains unknown.

289 mulation test in patients with cirrhosis and gastroesophageal variceal bleeding.

290 tify the incidence and predictors of de novo gastroesophageal variceal formation and progression in a

291 ich may induce lethal complications, such as gastroesophageal variceal hemorrhage and hepatic encepha

292 clinical trial to assess the development of gastroesophageal varices (GEV).

293 inding at least moderate hepatic fibrosis or gastroesophageal varices (GOV) at oesophago-gastroduoden

294 es vs 128 degrees ; P = .008), less frequent gastroesophageal varices (three of 19 [16%] vs 20 of 41

295 We assessed the course of gastroesophageal varices in a large cohort of patients w

296 eeded to eradicate varices; no bleeding from gastroesophageal varices was observed after eradication.

297 Among 210 patients with existing gastroesophageal varices, 74 (35.2%) had variceal progre

298 tension (PH) has been exclusively devoted to gastroesophageal varices-related events at different fra

299 children with biliary atresia and high-risk gastroesophageal varices.

300 derwent both CT and endoscopic screening for gastroesophageal varices.